NICE Recommends Takeda’s Ninlaro Treatment Combo for Multiple Myeloma

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Takeda’s Ninlaro (ixazomib) in combination with lenalidomide and dexamethasone for National Health Service (NHS) use in the treatment of adult patients with multiple myeloma who have had two or three lines of therapy.

The agency decided to recommend the treatment combination because it fills an unmet need, despite some uncertainty after reviewing the supporting data.

Ninlaro is administered orally on days one, eight and 15 of a 28-day cycle. A negotiated price for NHS use was not disclosed, but the UK market price is approximately 6,300 pounds Sterling for three capsules.